Thursday, 1 December 2016

Patent Feud Is Underappreciated Risk at Biogen

Biogen’s big patent dispute puts blockbuster drug revenues at risk.

from WSJ.com: Markets http://ift.tt/2fJuo2c
via https://ifttt.com/ IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)